Search results for " allergy"

showing 10 items of 3043 documents

Combining Three Different Pretransplantation Scores Improves Predictive Value in Patients after Haploidentical Stem Cell Transplantation with Thiotep…

2021

ABSTRACT One hundred and sixty-one patients underwent haploidentical stem cell transplantation (haploSCT) with thiotepa, busulfan, and fludarabine conditioning followed by post-transplantation cyclophosphamide (PTCy) (on days +3 and +4) and tacrolimus as graft-versus-host disease prophylaxis. Forty-two percent of patients had a high or very high revised Disease Risk Index (rDRI), 55% had an European Society for Blood and Marrow Transplantation risk score (EBMT-RS) ≥4, and 36% had an age-adjusted Hematopoietic Cell Transplant Comorbidity Index (HCT-CI-age) score ≥3. Each of these was considered an unfavorable score. Using the pretransplantation unfavorable scores that had an independent impa…

medicine.medical_specialtyTransplantation ConditioningPredictive transplantation scoresCyclophosphamideAcute myelogenous leukemiaGraft vs Host DiseaseThioTEPAInternal medicinemedicineHumansImmunology and AllergyBusulfanCyclophosphamideTransplantationFramingham Risk Scorebusiness.industryIncidence (epidemiology)Hematopoietic Stem Cell TransplantationCell BiologyHematologyHaploidentical transplantation with TBF conditioningTacrolimusFludarabineTransplantationsurgical procedures operativeMolecular MedicinebusinessThiotepaVidarabineBusulfanmedicine.drugTransplantation and Cellular Therapy
researchProduct

What Is the Impact of Innovative Electronic Health Interventions in Improving Treatment Adherence in Asthma? The Pediatric Perspective

2019

Suboptimal adherence to treatment is a significant issue in the management of pediatric asthma and is a major cause of uncontrolled disease, life-threatening attacks, and increased utilization of healthcare resources. Electronic health (e-Health) solutions have the potential to positively impact asthma self-management in children and adolescents and their families, thereby improving treatment adherence and asthma outcomes. However, there is a lack of sufficient data to support widespread adoption of e-Health tools in pediatric asthma practice. A critical evaluation of the impact of these new interventions on treatment adherence in childhood asthma must consider unmet needs, heterogeneity of…

medicine.medical_specialtyTreatment adherencePsychological interventionMobile applicationDiseaseElectronic monitoring devicesPediatrics03 medical and health sciences0302 clinical medicineMobile applicationsInventionsAsthma controlHealth caremedicineHumansImmunology and Allergy030212 general & internal medicineChildIntensive care medicinemHealthChildrenAsthmaChildhood asthmabusiness.industryPerspective (graphical)medicine.diseaseQuality ImprovementTelemedicineAsthmaTreatment Adherence and ComplianceItaly030228 respiratory systemElectronic monitoring deviceAdherencee-Healthbusiness
researchProduct

Update on the principles and novel local and systemic therapies for the treatment of non-infectious uveitis.

2012

Ocular inflammatory disorders constitute a sight-threatening group of diseases that might be managed according to their severity. Their treatment guidelines experience constant changes with new agents that improve the results obtained with former drugs. Nowadays we can make use of a five step protocol in which topical, periocular and systemic corticosteroids remain as the main therapy for non-infectious uveitis. In addition, immunosuppresive drugs can be added in order to enhance the anti-inflammatory effects and to play the role of corticosteroid-sparing agents. These can be organized in four other steps: cyclosporine and methotrexate in a second one; azathioprine, mycophenolate and tacrol…

medicine.medical_specialtyTreatment protocolCyclophosphamideAdministration TopicalImmunologyAnti-Inflammatory AgentsAzathioprineUveitisInfectious uveitisAdrenal Cortex HormonesmedicineImmunology and AllergyAnimalsHumansIntensive care medicinePharmacologyChlorambucilbusiness.industryTumor Necrosis Factor-alphaGeneral Medicinemedicine.diseaseTacrolimusSurgeryInjections IntravenousPractice Guidelines as TopicMethotrexateImmunotherapybusinessUveitisAlgorithmsImmunosuppressive Agentsmedicine.drugInflammationallergy drug targets
researchProduct

Tamoxifen, a Trigger Factor of Hereditary Angioedema with Normal C1-INH with a Specific Mutation in the F12 Gene (HAE-FXII)

2016

medicine.medical_specialtyTrigger factorSpecific mutationbusiness.industryImmunologymedicine.diseaseEndocrinologyInternal medicineHereditary angioedemamedicineCancer researchImmunology and AllergybusinessGeneTamoxifenmedicine.drugJournal of Allergy and Clinical Immunology
researchProduct

GENOMIC EPIDEMIOLOGY OF TUBERCULOSIS: FROM WITHIN HOST EVOLUTION TO GLOBAL MIGRATION PATTERNS

2018

.

medicine.medical_specialtyTuberculosisHost (biology)ImmunologyInfectious and parasitic diseasesRC109-216Global migrationBiologymedicine.diseaseInfectious DiseasesEvolutionary biologyEpidemiologymedicineImmunology and AllergyRussian Journal of Infection and Immunity
researchProduct

Sustained safety and efficacy of ligelizumab in patients with chronic spontaneous urticaria: A one‐year extension study

2021

Background: Ligelizumab, a next-generation, humanized anti-immunoglobulin E (IgE) monoclonal antibody is in development as a treatment for patients with chronic spontaneous urticaria, whose symptoms are inadequately controlled with standard-of-care therapy. Objective: To evaluate the long-term safety and re-treatment efficacy of ligelizumab 240 mg in patients who completed the core study and extension study. Methods: This open-label, single-arm, long-term Phase 2b extension study was designed to assess patients who were previously administered various doses of ligelizumab, omalizumab or placebo in the Phase 2b, dose-finding core study and who presented with active disease after Week 32. In …

medicine.medical_specialtyUrticariaImmunologyLigelizumab610OmalizumabOmalizumabImmunoglobulin EPlaceboAntibodies Monoclonal HumanizedInternal medicineActive diseasemedicineImmunology and AllergyHumansIn patientChronic UrticariaAdverse effectbiologybusiness.industryExtension studyChronic spontaneous urticariaTreatment OutcomeLigelizumabbiology.proteinIgEbusiness600 Technik Medizin angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheitmedicine.drug
researchProduct

Peltier effect-based temperature challenge: an improved method for diagnosing cold urticaria.

2004

medicine.medical_specialtyUrticariabusiness.industryThermometersImmunologyImproved methodCold urticariamedicine.diseaseDermatologySurgeryCold TemperatureSemiconductorsThermoelectric effectImmunology and AllergyMedicineHumansbusinessThe Journal of allergy and clinical immunology
researchProduct

OP0062-HPR Efficacy of Tailored Exercise Therapy in Patients with Knee Osteoarthritis and Comorbidity: A Randomized Controlled Trial

2016

Background Exercise therapy is a key intervention in the management of knee osteoarthritis (OA). It is an effective intervention to improve physical functioning and reduce joint pain in patients with knee OA. Comorbidity, which is highly prevalent in OA, interferes with the application of exercise therapy and contributes to non-adherence to exercise therapy. Objectives To evaluate the efficacy and safety of tailored exercise therapy on physical functioning in patients with knee osteoarthritis (OA) and comorbidity Methods A randomized clinical controlled trial was performed, comparing comorbidity-adapted exercise therapy with a control intervention. The study was conducted in an outpatient r…

medicine.medical_specialtyWOMACbusiness.industryImmunologyOsteoarthritismedicine.diseaseComorbidityGeneral Biochemistry Genetics and Molecular Biologylaw.inventionRheumatologyRandomized controlled triallawRating scaleJoint painHeart failuremedicinePhysical therapyImmunology and Allergymedicine.symptomAdverse effectbusinessAnnals of the Rheumatic Diseases
researchProduct

Clinical Development of Mepolizumab for the Treatment of Severe Eosinophilic Asthma: On the Path to Personalized Medicine.

2021

The development of mepolizumab, an anti-IL-5 monoclonal antibody for the treatment of severe eosinophilic asthma, is an example of a clinical development program that evolved over time based on sound, basic scientific principles. Initial clinical data on the effects of mepolizumab on lung function in a general asthmatic population were disappointing. However, it became clear that mepolizumab may be more effective against other clinical endpoints, particularly asthma exacerbations, in patients with more severe disease. Furthermore, a developing understanding of asthma disease pathobiology led to the identification of an appropriate target population and predictive biomarker for mepolizumab t…

medicine.medical_specialty[SDV]Life Sciences [q-bio]PopulationDiseaseAntibodies Monoclonal Humanized03 medical and health sciences0302 clinical medicineClinical endpointImmunology and AllergyMedicineHumans030212 general & internal medicineAnti-Asthmatic AgentsPrecision MedicineIntensive care medicineAdverse effecteducationComputingMilieux_MISCELLANEOUSAsthmaeducation.field_of_studybusiness.industrymedicine.diseaseAsthmaEosinophils030228 respiratory systemAsthma Control QuestionnairePersonalized medicinebusinessMepolizumabmedicine.drugThe journal of allergy and clinical immunology. In practice
researchProduct

Long-term efficacy of omalizumab (OMA) for patients with severe allergic asthma (SAA). Clinical assessment and relationship to serum IgE concentratio…

2015

Background: OMA is an effective treatment option in SAA. However, little data are available on the long-term-efficacy oft the drug. Objective: To determine the long-term efficacy of OMA in respect to clinical parameters and IgE serum levels. Methods: This was a retrospective, open-label, uncontrolled, multi-center observational study according to the definition of non-interventional studies. 22 non-smoking patients (10 m, 12 f; mean age 47,9 yrs) with SAA were enrolled. Pat were treated with OMA up to for 4 years and total serum IgE levels were assessed at initiation of therapy, after 2-6 ms and 3-5 yrs. Data were recorded on standardized CRFs by the treating physician. Results: The average…

medicine.medical_specialtybiologybusiness.industryAllergic asthmaAtopic dermatitisOmalizumabImmunoglobulin Emedicine.diseaseGastroenterologyTreatment periodSerum igeFood allergyInternal medicineConcomitantImmunologybiology.proteinmedicinebusinessmedicine.drug5.3 Allergy and Immunology
researchProduct